Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 10;23(19):12041.
doi: 10.3390/ijms231912041.

Molecular Biomarkers for the Early Detection of Ovarian Cancer

Ruiqian Zhang  1 , Michelle K Y Siu  1 , Hextan Y S Ngan  1 , Karen K L Chan  1
Affiliations
Review

Molecular Biomarkers for the Early Detection of Ovarian Cancer

Ruiqian Zhang et al. Int J Mol Sci. .

Abstract

Ovarian cancer is the deadliest gynecological cancer, leading to over 152,000 deaths each year. A late diagnosis is the primary factor causing a poor prognosis of ovarian cancer and often occurs due to a lack of specific symptoms and effective biomarkers for an early detection. Currently, cancer antigen 125 (CA125) is the most widely used biomarker for ovarian cancer detection, but this approach is limited by a low specificity. In recent years, multimarker panels have been developed by combining molecular biomarkers such as human epididymis secretory protein 4 (HE4), ultrasound results, or menopausal status to improve the diagnostic efficacy. The risk of ovarian malignancy algorithm (ROMA), the risk of malignancy index (RMI), and OVA1 assays have also been clinically used with improved sensitivity and specificity. Ongoing investigations into novel biomarkers such as autoantibodies, ctDNAs, miRNAs, and DNA methylation signatures continue to aim to provide earlier detection methods for ovarian cancer. This paper reviews recent advancements in molecular biomarkers for the early detection of ovarian cancer.

Keywords: CA125; HE4; RMI; ROMA; molecular biomarkers; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet. 2014;384:1376–1388. doi: 10.1016/S0140-6736(13)62146-7. - DOI - PubMed
    1. Hinchcliff E., Westin S.N., Herzog T.J. State of the science: Contemporary front-line treatment of advanced ovarian cancer. Gynecol. Oncol. 2022;166:18–24. doi: 10.1016/j.ygyno.2022.04.021. - DOI - PubMed
    1. Bartoletti M., Musacchio L., Giannone G., Tuninetti V., Bergamini A., Scambia G., Lorusso D., Valabrega G., Mangili G., Puglisi F., et al. Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. Cancer Treat. Rev. 2021;101:102298. doi: 10.1016/j.ctrv.2021.102298. - DOI - PubMed
    1. Pierce S.R., Clark L.H. Current first-line therapy for ovarian cancer: A comprehensive review. Obstet. Gynecol. Surv. 2017;33:792–793. doi: 10.1097/OGX.0000000000000613. - DOI - PubMed